Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.5360 -0.0840 (-13.55%)
Streaming Delayed Price Updated: 11:50 AM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances IP Portfolio With EPO Notice of Intent to Grant Patent
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
From Silo Pharma, Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Authorizes $1 Million Share Repurchase Program
Via Investor Brand Network
News headline image
Silo Pharma Announces Share Buyback Program
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives Japan Patent Allowance for SPC-15 PTSD Candidate10
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
Patent strengthens protection for novel PTSD drug and advances the Company’s international IP strategy 
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
Highly secure, institutional-grade infrastructure supports Bitcoin, Ethereum and Solana treasury strategy 
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expects SPC-15 PTSD Study Results Within 90 Days
Via Investor Brand Network
News headline image
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Via Get News
Topics Intellectual Property
News headline image
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Via Press Release Distribution Service
Topics Intellectual Property
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives USPTO Notice of Allowance for PTSD Treatment Patent
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.